Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €98.40 EUR
Change Today -2.60 / -2.57%
Volume 19.6K
BIM On Other Exchanges
BIM is not on other exchanges.
As of 8:38 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

biomerieux (BIM) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - €109.65
52 Week Low
09/3/14 - €76.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOMERIEUX (BIM)

Related News

No related news articles were found.

biomerieux (BIM) Related Businessweek News

No Related Businessweek News Found

biomerieux (BIM) Details

bioMérieux S.A. provides in vitro diagnostics solutions that determine the source of disease and contamination to enhance patient health and consumer safety worldwide. The company offers reagents, instruments, and software for diagnosing infectious diseases, healthcare-associated infections, antimicrobial resistance, sepsis, acquired immunodeficiency syndrome, hepatitis, acute care and cardiovascular emergencies, and cancer; and for detecting microorganisms in agri-food, pharmaceutical, biotechnology, and cosmetic products. Its technologies and systems include clinical microbiology products, such as automated VITEK 2 system and Etest for the identification of bacteria and analysis of their susceptibility to antibiotics; VITEK MS, a mass spectrometry-based system for the identification of bacteria, fungi, and mycobacteria; culture media products; BacT/ALERT for the culture and detection of bacteria present in blood; Full Microbiology Lab Automation system; and molecular diagnostics products. The company also provides immunoassays products comprising VIDAS, an immunoassay system; and bioNexia and VIKIA range of products for conducting rapid tests. In addition, it offers molecular biology products, including NucliSENS easyMAG and NucliSENS miniMAG for extraction; and ARGENE and NucliSENS EasyQ for amplification and detection. Further, the company offers industrial microbiology products, such as bacteriophages and cytometry products; and TEMPO, an automated microbiological testing system for food-processing applications. Additionally, the company provides Myla, an information technology solution for microbiology laboratories; PREVI Isola, an automated inoculation system for culture media; and PREVI color gram for the automated gram staining of sample slides containing microorganisms. The company, formerly known as B-D Mérieux, was founded in 1963 and is headquartered in Marcy l’Etoile, France. bioMérieux SA operates as a subsidiary of Institut Mérieux SA.

8,062 Employees
Last Reported Date: 04/28/15
Founded in 1963

biomerieux (BIM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €669.5K
Compensation as of Fiscal Year 2014.

biomerieux (BIM) Key Developments

bioMérieux SA Announces Audited Consolidated Earnings Results for the First Half Ended June 30, 2015; Provides Earnings Guidance for the Full Year 2015

bioMérieux SA announced audited consolidated earnings results for the first half ended June 30, 2015. For the period, the company reported sales of EUR 933 million against EUR 781 million a year ago. Contributive operating income before non-recurring items was EUR 122 million against EUR 91 million a year ago. Operating income was EUR 103 million against EUR 78 million a year ago. Operating income before non-recurring items stood at EUR 104 million, compared with EUR 76 million a year earlier. Against a backdrop of significant operational and industrial investment, net debt amounted to EUR 274 million at June 30, 2015, against EUR 249 million at December 31, 2014. Net income of consolidated companies was EUR 59.1 million against EUR 50.6 million a year ago. Net income attributable to the parent company was EUR 59.6 million against EUR 50.4 million a year ago. Diluted earnings per share were EUR 1.51 against EUR 1.28 a year ago. EBITDA (before non-recurring items) was EUR 178.8 million against EUR 140.9 million a year ago. Net cash flow from operations was EUR 109.6 million against EUR 107.1 million a year ago. Purchase of property, plant and equipment was EUR 86.1 million against EUR 56.1 million a year ago. Based on the current business outlook, the company maintains its objective of reporting between 4.5% and 6.5% organic growth in sales in 2015, at constant exchange rates and scope of consolidation. It is also maintaining its contributive operating income before non-recurring items target of between EUR 240 million and EUR 265 million for the year. In an unstable economic environment, the company remains confident about the strength of the performance expected for 2015 in relation to the objectives set.

bioMérieux Receives FDA 510(K) Clearance for VIDAS® 3

bioMérieux announced that VIDAS® 3, the new generation of VIDAS®, received FDA 510(k) clearance. This instrument, which further enriches the offering of the VIDAS® immunoassay product range, VIDAS® and mini VIDAS®, is now commercially available in the United States. VIDAS® 3 features enhanced automation, in particular the pre-analytical section from the barcoded primary tube including dilution, improved traceability and new software capabilities, as well as a quality control program in compliance with laboratory certification standards. Designed with the help of 1,500 immunoassay laboratories, this new-generation instrument has received an enthusiastic reception by laboratory professionals. VIDAS® 3 uses the same reagents as the other instruments in the VIDAS® range. At launch in the U.S., VIDAS® 3 menu features specialty and high medical value tests, such as IDAS® B·R·A·H·M·S PCT™ for the management of septic patients. The single test concept and new features make the VIDAS® 3 particularly well adapted to meet the needs of labs supporting Emergency Departments and Critical Care.

bioMérieux Reports Earnings Results for the Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year 2015

bioMérieux reported earnings results for the six months ended June 30, 2015. For the period, consolidated sales amounted to €933 million, up from €781 million in the year-earlier period. This represented growth of 8.1% like-for-like and of 9.1% after changes in the scope of consolidation related to the BioFire and CEERAM acquisitions. Net debt amounted to €274 million at June 30, 2015 after payment of the dividend versus €249 million at December 31, 2014. Based on the current sales outlook, the company is confident that it will meet its objective of reporting between 4.5% and 6.5% organic growth in sales in 2015, at constant exchange rates and scope of consolidation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIM:FP €98.40 EUR -2.60

BIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $51.97 USD -0.78
Bio-Rad Laboratories Inc $139.33 USD -0.19
Bruker Corp $18.38 USD -0.20
Cepheid $48.74 USD -1.62
QIAGEN NV €22.88 EUR -0.52
View Industry Companies

Industry Analysis


Industry Average

Valuation BIM Industry Range
Price/Earnings 27.6x
Price/Sales 2.2x
Price/Book 2.7x
Price/Cash Flow 27.6x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERIEUX, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at